Cancer Immunotherapy Market

Cancer Immunotherapy Market (Therapy Type: Monoclonal Antibodies, Immune Checkpoint Inhibitors, PD-1/PD-L1, CTLA-4, Immune System Modulators, Cancer Vaccines, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Cancer Immunotherapy Market Outlook 2031

  • The global cancer immunotherapy market was valued over US$ 82.8 Bn in 2021
  • It is estimated to grow at a CAGR of 13.6% from 2022 to 2031
  • The global cancer immunotherapy market is expected to cross value of US$ 261.7 Bn by the end of 2031

Analysts’ Viewpoint on Global Cancer Immunotherapy Market Scenario

Novel innovations as a result of rise in the R&D activities are driving the cancer immunotherapy market. For instance, on June 6, 2022, a major clinical breakthrough was witnessed in the treatment of cancer with the development of a drug called dostarlimb, which is effective against the rectal cancer. Moreover, various companies are highly investing in the market, which creates a ‘big cheese’ for the cancer immunotherapy market. Hence, the popularity of cancer Immunotherapy treatment among the patients due to its cost friendliness and less side effects is one of the major reasons for the growth of the cancer immunotherapy market.

cancer immunotherapy market

Overview of Global Cancer Immunotherapy Market

Immunotherapy is a cancer treatment that improves the immune system's ability to fight cancer. It is a kind of biological treatment. Biological therapy makes use of compounds derived from biological creatures or lab-created copies of these substances.

Increase in R&D activities, improvements in efficacy & accuracy of newer medicines, surge in adoption of target therapy over standard therapy, and rise in prevalence of cancer are the major factors propelling the global cancer immunotherapy market. In addition, rise in incidence of cancer is a key factor driving the global cancer immunotherapy market. In the U.S., cancer is the biggest cause of mortality and disease, and it not only has a significant effect on the health of patients and survivors, but also has a major financial impact.

Several companies are increasingly investing in R&D activities to develop more effective treatments for cancer. For instance, TILT Bio therapeutics has announced over $10 million financing to the oncology immunotherapy assets. Companies such as Justin Wilson, partner & attorney at Withers & Rodgers, have discussed their opinion on innovations in the microbe in supporting the discovery of new drugs & treatments in the immunotherapy market.

Request a sample to get extensive insights into the Cancer Immunotherapy Market

Popularity of Cancer Immunotherapy Treatment among Patients Due to Cost-effectiveness and Less Side Effects

In terms of therapy type, the global cancer immunotherapy market has been classified into immune system modulators, immune checkpoint inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. Monoclonal antibodies have been the treatment method of choice for a large segment of the global healthcare industry, giving it a significant advantage over other segments. Monoclonal antibodies have gained, as it is less expensive than other therapies. However, the global cancer immunotherapy market is expected to witness increase in demand for immune checkpoint inhibitors due to higher success rates and overall efficiency.

Based on therapeutic area, the global cancer immunotherapy market has been categorized into blood cancer, prostate cancer, melanoma, breast cancer, lung cancer, colorectal cancer, and other minor cancers. Breast cancer has been the most common target for immunotherapy. Increase in population of smokers and rise in total air pollution in metropolitan areas drive the lung cancer segment.

Rise in R&D Activities and High Efficacy of Newer Therapies to Augment Market

Rise in R&D activities in the field of cancer immunotherapy has led to the introduction of advanced variants with improved treatment efficacy and effectiveness. Immuno oncology has shown promising results in terms of increased survival and decreased toxicity. The market is likely to be propelled by a paradigm shift from traditional chemotherapies to immunotherapies. Immunotherapies in development are expected to offer more treatment options and better outcomes than currently available therapies. The introduction of newer drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, aimed at multiple myeloma receptors, is projected to propel the global market. The market is likely to be driven by ongoing research on similar drugs with the goal of reducing side effects.

Monoclonal Antibodies to Remain Dominant Immunotherapeutic Drugs in Global Market

In terms of therapy type, the global cancer immunotherapy market has been classified into monoclonal antibodies, immune checkpoint inhibitors, PD-1/PD-L1, CTLA-4, immune system modulators, cancer vaccines, and others. The monoclonal antibody segment accounted for key market share in 2021. Monoclonal antibodies are the most commonly prescribed immunotherapeutic drugs in the world. Following Amgen's approval of Blincyto (blinatumomab), a bispecific antibody that targets B-cell lymphoblastic leukemia, monoclonal antibodies were developed as effective immunotherapeutic options.

Increase in research & development on the use of monoclonal bodies as naked antigen binding antibodies, conjugated antibodies, and bispecific antibodies has led to the discovery of new cancer therapeutic options.

High Cost of Cancer Immunotherapy Manufacturing R&D to Hamper Global Market Growth

The global cancer immunotherapy market is concerned about both research and manufacturing costs as well as market price for the end-user. For a developing organization, cancer immunotherapy research & development requires large amounts of resources, which raises worries about receiving finances. Research activities involving new technology development require significant investment, which is expected to be received with significant profits by the innovator. Cancer immunotherapy is a niche segment and requires high investment. This deters companies to enter the market due to uncertainty of receiving expected profit.

Regional Outlook of Global Cancer Immunotherapy Market

In terms of region, the global cancer immunotherapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is projected to be a highly lucrative market for cancer immunotherapy during the forecast period. Well-established healthcare infrastructure and increase in government initiatives are the major factors driving the market in the region. North America's large market share can be attributed to rise in number of patients suffering from cancer, increase in adoption rate of immunotherapy, and development of bioinformatics tools that enhance the drug development process.

The market in Asia Pacific is expected to experience the fastest growth during the forecast period. New and advanced immunotherapy drugs have been introduced in China and Japan. These countries have several ongoing clinical trials as well as FDA approvals for new drug molecules and combination therapies. Approval of new treatment drugs in China and Japan boosts the adoption of immunotherapy for treatment of tumors.

Analysis of Key Players in Global Cancer Immunotherapy Market

This report profiles major players in the global cancer immunotherapy market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global cancer immunotherapy market is quite competitive, with the top players accounting for major share of the market and companies focusing on research & development to produce better pharmaceutical products for the existing diseases.

Leading players operating in the global cancer immunotherapy market are Amgen, Inc., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Sanofi, Janssen Biotech, Inc., Merck & Co., Inc., Pfizer, Inc., Spectrum Pharmaceuticals, Inc., Novartis AG, and Takeda Pharmaceuticals.

Request a custom report on Cancer Immunotherapy Market

Key Developments in Global Cancer Immunotherapy Market

Key players in the global cancer immunotherapy market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global cancer immunotherapy market. A few expansion strategies adopted by players operating in the global cancer immunotherapy market are:

  • In February 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM)
  • In April 2021, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer as well as esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

Global Cancer Immunotherapy Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 82.8 Bn

Market Forecast Value in 2028

US$ 261.7 Bn

Growth Rate (CAGR)

13.6%

Forecast Period

2022–2031

Historical Data Available for

2017-2020

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Therapy Type
    • Monoclonal Antibodies
    • Immune Checkpoint Inhibitors
    • PD-1/PD-L1
    • CTLA-4
    • Immune System Modulators
    • Cancer Vaccines
    • Others
  • Therapeutic Area
    • Lung Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Prostate Cancer
    • Melanoma
    • Blood Cancers
    • Others
  • End-user
    • Hospitals
    • Ambulatory Surgical Centers (ASCs)
    • Cancer Research Centers
    • Clinics

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Janssen Biotech, Inc.
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Novartis AG
  • Takeda Pharmaceuticals
  • Other Prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global cancer immunotherapy market in 2021?

The global cancer immunotherapy market was valued over US$ 82.8 Bn in 2021

How big will be the cancer immunotherapy market in 2031?

The global cancer immunotherapy market is expected to surpass US$ 261.7 Bn by 2031

What is the CAGR of global cancer immunotherapy market during the forecast period (2022-2031)?

The global cancer immunotherapy market is anticipated to record CAGR of 13.6% from 2022 to 2031

What are the prominent trends impacting market growth?

Rise in R&D Activities, increase in effectivity & accuracy of newer therapies, and popularity of cancer immunotherapy treatment

Which region held key market share during the forecast period?

North America is expected to be a potential revenue generator for vendors during the forecast period

Who are the prominent players in the global cancer immunotherapy market?

Prominent players in the global cancer immunotherapy market include Amgen, Inc. Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Sanofi, Janssen Biotech, Inc., Merck & Co., Inc. Pfizer, Inc, Spectrum Pharmaceuticals, Inc., Novartis AG, and Takeda Pharmaceuticals.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Cancer Immunotherapy Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Cancer Immunotherapy Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Value Chain Analysis

        5.2. Pipeline Analysis

        5.3. Cancer Epidemiology

        5.4. COVID-19 impact

    6. Global Cancer Immunotherapy Market Analysis and Forecast, by Therapy Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Therapy Type, 2017–2031

            6.3.1. Monoclonal Antibodies

            6.3.2. Immune Checkpoint Inhibitors

            6.3.3. PD-1/PD-L1

            6.3.4. CTLA-4

            6.3.5. Immune System Modulators

            6.3.6. Cancer Vaccines

            6.3.7. Others

        6.4. Market Attractiveness Analysis, by Therapy Type

    7. Global Cancer Immunotherapy Market Analysis and Forecast, by Therapeutic Area

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Therapeutic Area, 2017–2031

            7.3.1. Lung Cancer

            7.3.2. Colorectal Cancer

            7.3.3. Breast Cancer

            7.3.4. Prostate Cancer

            7.3.5. Melanoma

            7.3.6. Blood Cancer

            7.3.7. Others

        7.4. Market Attractiveness Analysis, by Therapeutic Area

    8. Global Cancer Immunotherapy Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by End-user, 2017–2031

            8.3.1. Hospitals

            8.3.2. Ambulatory Surgical Centers (ASCs)

            8.3.3. Cancer Research Centers

            8.3.4. Clinics

        8.4. Market Attractiveness Analysis, by End-user

    9. Global Cancer Immunotherapy Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Cancer Immunotherapy Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Therapy Type, 2017–2031

            10.2.1. Monoclonal Antibodies

            10.2.2. Immune Checkpoint Inhibitors

            10.2.3. PD-1/PD-L1

            10.2.4. CTLA-4

            10.2.5. Immune System Modulators

            10.2.6. Cancer Vaccines

            10.2.7. Others

        10.3. Market Value Forecast, by Therapeutic Area, 2017–2031

            10.3.1. Lung Cancer

            10.3.2. Colorectal Cancer

            10.3.3. Breast Cancer

            10.3.4. Prostate Cancer

            10.3.5. Melanoma

            10.3.6. Blood Cancer

            10.3.7. Others

        10.4. Market Value Forecast, by End-user, 2017–2031

            10.4.1. Hospitals

            10.4.2. Ambulatory Surgical Centers (ASCs)

            10.4.3. Cancer Research Centers

            10.4.4. Clinics

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Therapy Type

            10.6.2. By Therapeutic Area

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Cancer Immunotherapy Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Therapy Type, 2017–2031

            11.2.1. Monoclonal Antibodies

            11.2.2. Immune Checkpoint Inhibitors

            11.2.3. PD-1/PD-L1

            11.2.4. CTLA-4

            11.2.5. Immune System Modulators

            11.2.6. Cancer Vaccines

            11.2.7. Others

        11.3. Market Value Forecast, by Therapeutic Area, 2017–2031

            11.3.1. Lung Cancer

            11.3.2. Colorectal Cancer

            11.3.3. Breast Cancer

            11.3.4. Prostate Cancer

            11.3.5. Melanoma

            11.3.6. Blood Cancer

            11.3.7. Others

        11.4. Market Value Forecast, by End-user, 2017–2031

            11.4.1. Hospitals

            11.4.2. Ambulatory Surgical Centers (ASCs)

            11.4.3. Cancer Research Centers

            11.4.4. Clinics

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Therapy Type

            11.6.2. By Therapeutic Area

            11.6.3. By End-user

            11.6.4. By Country/Sub-region

    12. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Therapy Type, 2017–2031

            12.2.1. Monoclonal Antibodies

            12.2.2. Immune Checkpoint Inhibitors

            12.2.3. PD-1/PD-L1

            12.2.4. CTLA-4

            12.2.5. Immune System Modulators

            12.2.6. Cancer Vaccines

            12.2.7. Others

        12.3. Market Value Forecast, by Therapeutic Area, 2017–2031

            12.3.1. Lung Cancer

            12.3.2. Colorectal Cancer

            12.3.3. Breast Cancer

            12.3.4. Prostate Cancer

            12.3.5. Melanoma

            12.3.6. Blood Cancer

            12.3.7. Others

        12.4. Market Value Forecast, by End-user, 2017–2031

            12.4.1. Hospitals

            12.4.2. Ambulatory Surgical Centers (ASCs)

            12.4.3. Cancer Research Centers

            12.4.4. Clinics

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Therapy Type

            12.6.2. By Therapeutic Area

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America Cancer Immunotherapy Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Therapy Type, 2017–2031

            13.2.1. Monoclonal Antibodies

            13.2.2. Immune Checkpoint Inhibitors

            13.2.3. PD-1/PD-L1

            13.2.4. CTLA-4

            13.2.5. Immune System Modulators

            13.2.6. Cancer Vaccines

            13.2.7. Others

        13.3. Market Value Forecast, by Therapeutic Area, 2017–2031

            13.3.1. Lung Cancer

            13.3.2. Colorectal Cancer

            13.3.3. Breast Cancer

            13.3.4. Prostate Cancer

            13.3.5. Melanoma

            13.3.6. Blood Cancer

            13.3.7. Others

        13.4. Market Value Forecast, by End-user, 2017–2031

            13.4.1. Hospitals

            13.4.2. Ambulatory Surgical Centers (ASCs)

            13.4.3. Cancer Research Centers

            13.4.4. Clinics

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Therapy Type

            13.6.2. By Therapeutic Area

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Cancer Immunotherapy Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Therapy Type, 2017–2031

            14.2.1. Monoclonal Antibodies

            14.2.2. Immune Checkpoint Inhibitors

            14.2.3. PD-1/PD-L1

            14.2.4. CTLA-4

            14.2.5. Immune System Modulators

            14.2.6. Cancer Vaccines

            14.2.7. Others

        14.3. Market Value Forecast, by Therapeutic Area, 2017–2031

            14.3.1. Lung Cancer

            14.3.2. Colorectal Cancer

            14.3.3. Breast Cancer

            14.3.4. Prostate Cancer

            14.3.5. Melanoma

            14.3.6. Blood Cancer

            14.3.7. Others

        14.4. Market Value Forecast, by End-user, 2017–2031

            14.4.1. Hospitals

            14.4.2. Ambulatory Surgical Centers (ASCs)

            14.4.3. Cancer Research Centers

            14.4.4. Clinics

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Therapy Type

            14.6.2. By Therapeutic Area

            14.6.3. By End-user

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2021

        15.3. Company Profiles

            15.3.1. Amgen, Inc.

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Financial Analysis

                15.3.1.3. Growth Strategies

                15.3.1.4. SWOT Analysis

            15.3.2. F. Hoffmann-La Roche Ltd.

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Financial Analysis

                15.3.2.3. Growth Strategies

                15.3.2.4. SWOT Analysis

            15.3.3. Bristol-Myers Squibb Company

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Financial Analysis

                15.3.3.3. Growth Strategies

                15.3.3.4. SWOT Analysis

            15.3.4. Merck & Co., Inc.

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Financial Analysis

                15.3.4.3. Growth Strategies

                15.3.4.4. SWOT Analysis

            15.3.5. Spectrum Pharmaceuticals

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Financial Analysis

                15.3.5.3. Growth Strategies

                15.3.5.4. SWOT Analysis

            15.3.6. GlaxoSmithKline plc

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Financial Analysis

                15.3.6.3. Growth Strategies

                15.3.6.4. SWOT Analysis

            15.3.7. Pfizer, Inc.

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Financial Analysis

                15.3.7.3. Growth Strategies

                15.3.7.4. SWOT Analysis

            15.3.8. AstraZeneca plc

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Financial Analysis

                15.3.8.3. Growth Strategies

                15.3.8.4. SWOT Analysis

            15.3.9. Eli Lilly and Company.

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Financial Analysis

                15.3.9.3. Growth Strategies

                15.3.9.4. SWOT Analysis

            15.3.10. Takeda Pharmaceuticals

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Financial Analysis

                15.3.10.3. Growth Strategies

                15.3.10.4. SWOT Analysis

    List of Tables

    Table 01: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

    Table 02: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

    Table 03: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

    Table 04: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Region, 2022 and 2031

    Table 05: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country, 2022 and 2031

    Table 06: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

    Table 07: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

    Table 08: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

    Table 09: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

    Table 10: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

    Table 11: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

    Table 12: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

    Table 13: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

    Table 14: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

    Table 15: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

    Table 16: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

    Table 17: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

    Table 18: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

    Table 19: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by therapeutic Area, 2022 and 2031

    Table 20: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

    Table 21: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

    Table 22: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

    Table 23: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area 2022 and 2031

    Table 24: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user 2022 and 2031

    List of Figures

    Figure 01: Global Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

    Figure 02: Global Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 03: Global Cancer Immunotherapy Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 04: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type, 2022 and 2031

    Figure 05: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

    Figure 06: Global Cancer Immunotherapy Market Attractiveness Analysis, by End-user, 2022 and 2031

    Figure 07: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, 2017–2028

    Figure 08: North America Cancer Immunotherapy Market Value Share Analysis, by Country, 2022 and 2031

    Figure 09: North America Cancer Immunotherapy Market Attractiveness Analysis, by Country, 2022 and 2031

    Figure 10: North America Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

    Figure 11: North America Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 12: North America Cancer Immunotherapy Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 13: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, 2017–2028

    Figure 14: Europe Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 15: Europe Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

    Figure 16: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

    Figure 17: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 18: Europe Cancer Immunotherapy Market Attractiveness Analysis, by End-user, 2022 and 2031

    Figure 1 9: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, 2017–2028

    Figure 20: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 21: Asia Pacific Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

    Figure 22: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

    Figure 23: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

    Figure 24: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 25: Latin America Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 26: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

    Figure 27: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type, 2022 and 2031

    Figure 28: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

    Figure 29: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

    Figure 30: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by End-user 2022 and 2031

    Figure 31: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 32: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

    Figure 33: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type, 2022 and 2031

    Figure 34: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

    Figure 35: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by End-user, 2022 and 2031

Copyright © Transparency Market Research, Inc. All Rights reserved